Equities

IOL Chemicals and Pharmaceuticals Ltd

IOL Chemicals and Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)486.45
  • Today's Change4.95 / 1.03%
  • Shares traded536.01k
  • 1 Year change-2.67%
  • Beta1.3706
Data delayed at least 15 minutes, as of Sep 20 2024 11:27 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of INR
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
ASSETS
Cash And Short Term Investments1,4282311,417
Total Receivables, Net5,2635,5255,141
Total Inventory4,3323,3464,157
Prepaid expenses1348279
Other current assets, total411916
Total current assets11,1989,20410,808
Property, plant & equipment, net10,2148,3266,625
Goodwill, net------
Intangibles, net1268934
Long term investments6632,5042,045
Note receivable - long term15128--
Other long term assets856763
Total assets22,44420,22119,623
LIABILITIES
Accounts payable4,6923,1424,093
Accrued expenses------
Notes payable/short-term debt328796428
Current portion long-term debt/capital leases01.8010
Other current liabilities, total581622603
Total current liabilities5,6004,5635,134
Total long term debt001.80
Total debt328798440
Deferred income tax661564532
Minority interest------
Other liabilities, total681833
Total liabilities6,3295,1445,700
SHAREHOLDERS EQUITY
Common stock587587587
Additional paid-in capital2,2572,2572,257
Retained earnings (accumulated deficit)13,35212,30211,145
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(82)(69)(67)
Total equity16,11515,07713,923
Total liabilities & shareholders' equity22,44420,22119,623
Total common shares outstanding595959
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.